Topic Listing for Genzyme

Access Accompanying Notes Integral Part Consolidated Financial Statements
Accord Satisfaction Accounting Impairment Long-lived Assets
Accounting Method Accounting Stock-based Compensation
Accounts Receivable Accrued Expenses
Accrued Expenses Amounts Acknowledged Agreed
Acquisition Alfigen Acquisition Anormed
Acquisition Assets Targeted Genetics Corporation Acquisition Bayer
Acquisition Bioenvision Acquisition Bone Care
Acquisition Equal Diagnostics Acquisition Gene Therapy Assets Avigen
Acquisition Gene Therapy Assets Avigen Inc Acquisition Ilex
Acquisition Ilex Oncology Acquisition Manufacturing Operation Cell Genesys
Acquisition Physician Services Analytical Business Units Impath Acquisition Physician Services Analytical Business Units Impath Inc
Acquisition Sangstat Acquisition Sangstat Medical Corporation
Acquisition Sirtris Gsk Acquisition Surgib
Acquisition Surgib Sas Acquisition Synvisc Sales Marketing Rights Wyeth
Acquisition Verigen Acquisitions
Acquisitions Product Growth Act
Actions Actions Proceedings
Activities Products Services Subject Significant Government Regulations Approvals Acts God
Addition Relevant Borrower Shall Pay Other Taxes Governmental Additional Agreements
Additional Insured Requirements Additional Provisions
Additional Rent Adjusted 2007
Adjustment Administration
Administration Eligibility Administration Plan Governing Law
Administration Plan Responsibility Committee Conjunction Ceo Vice President Administrative Agent
Administrative Agent Shall Promptly Notify Parent Borrower Each Adopted 2008
Adopting Shareholder Proposal Place Competitive Disadvantage Attracting Retaining Adoption Fas 123r
Affiliate Affirmative Covenants
Affirmative Covenants Pending Closing Shall Agents
Agreement Agreement Plan Merger
Agreements Dyax Agreements Dyax Corp
Agreements Dyax Corporation Agreements Shall Survive Repayment Obligations Other Amounts Payable
Agreements Shall Survive Termination Agreement Payment Loans Other Agrees Nothing Herein Shall Affect Right Effect Service
Alan Smith Aldurazyme
Aldurazyme Laronidase Alemtuzumab
Alemtuzumab Phase Trials Completes Enrollment Allocation Policy Related Tracking Stocks
Allocation Revenue Expenses Assets Liabilities Amended Restated Collaboration Agreement
Amended Restated Contract Manufacturing Agreement Amendment
Amendment 2004 Equity Incentive Plan Amendment Award
Amendment By-laws Amendment Leases
Amendment Plan Amendment Termination
Amendments Amendments Articles Incorporation Bylaws Change
Amendments Building 1400 Lease Amendments Building 600 Lease
Amortization Intangibles Amount
Amount Terms Commitments Amounts
Annual Meeting Broadcast Web Site Annual Meeting Information
Anormed Api Release
Applicable Law Applicable Law Construction
Approval Outside United States Arbitration
Aspects System Assignment
Assignment Subletting Attachment
Attestation Report Independent Registered Public Accounting Firm Audit Committee
Audit Committee Report Authority Execute Perform Agreement
Authority Oversee Control Manufacture Commercialization Aldurazyme Such Activities Authorized Amounts Designations
Authorized Buying Entities Authorized Capital Stock
Available Information Avigen
Award B-1
Base Salary Basis Presentation
Basis Presentation Principles Consolidation Bayer-development Alemtuzumab
Been Advised Counsel Negotiation Execution Delivery Agreement Other Been Advised Counsel Negotiation Execution Delivery Guarantee Other
Believe Severance Arrangements Best Interests Believe Severance Arrangements Place Senior Executives Best Interests
Beneficial Ownership Reporting Compliance Bind Inure Limitation Landlords Liability
Binding Effect Assignment Third-party Beneficiaries Bioenvision
Bioenvision Inc Biomarin
Biomarin Continue Manufacture Genzyme Market Sell Aldurazyme Biomarin Genzyme Llc
Biomarin Genzyme Llc Consolidated Statements Changes Venturers Capital Biomarin Genzyme Llc Index Consolidated Financial Statements
Biomarin Genzyme Restructure Aldurazyme Joint Venture Biomatrix
Biosurgery Biosurgery Refrigeration Transportation Requirements
Biosurgery Stock Biotherapeutics Llc
Board Approvals Anti-takeover Vote Required Board Directors
Board Directors Recommends Approve Board Directors Recommends Approve 2007 Director Equity Plan
Board Directors Recommends Ratify Selection Auditors 2007 Board Directors Recommends Shareholders Approve Amendment Bylaws Provide
Board Directors Recommends Vote Against Proposal Reasons Set Board Meetings Committees
Bona Fide Bone Care
Books Account Audit Genzyme Shall Keep Maintain Proper Brokerage
Building Lease Bulk
Bulk Specifications Business
Cambridge Antibody Technology Group Plc Cambridge New York
Campath Alemtuzumab Cancellation Insurance
Cancer Capital Expenditures
Capital Lease Capital Leases
Capital Stock Capitalization
Cardiac Device Assets Cardiometabolic Renal
Carrier Rating Cash
Cash Equivalents Cash Flows Financing Activities
Cash Flows Investing Activities Cash Flows Operating Activities
Cat Cercla
Cerezyme Cerezyme Fabrazyme
Cerezyme Fabrazyme Supply Constraints Resulting Suspension Production Allston Cerezyme Imiglucerase
Certain Other Adjustments Certain Relationships Related Persons Transactions
Certain Relationships Related Transactions Director Independence Certain Requirements Applicable Insurance Policies
Certificates Insurance Certification
Certification Chief Executive Officer Pursuant Usc 1350 Adopted Certification Chief Financial Officer Pursuant Usc 1350 Adopted
Certification Pursuant Rules 13a-14 15d-14 Securities Exchange Act Certification Suitability Monographs European Pharmacopoeia
Cgmp Change Control
Change Orders Changes Internal Control Over Financial Reporting
Charge Impaired Assets Charge Impaired Goodwill
Charge Impairment Goodwill Charges Impaired Investments
Charges Impairment Investments Charles Cooney
Charles Cooney Phd Check Appropriate Box
Claim Clofarabine Evoltra
Clolar Clofarabine Injection Clostridium Difficile
Code Collaboration Ptc
Collaboration Ptc Therapeutics Inc Collaborations
Collier Commitments Contingencies
Committee Discretion Committee Establishes Annual Bonus Targets Eligible Participants Upcoming
Common Area Maintenance Expenses Common Stock
Commonwealth Massachusetts Commonwealth Massachusetts William Francis Galvin Secretary Ashburton Place
Commonwealth Puerto Rico Guam American Samoa Northern Marianna Communication Audit Committees
Compensation Committee Compensation Committee Report
Compensation Committee Report Executive Compensation Discussion Analysis
Compensatory Arrangements Certain Officers Competition
Complaints Completion Acquisition Disposition Assets
Compliance 409a Compliance Law
Compliance Laws Components Net Periodic Benefit Costs
Composition Comprehensive Income
Comprehensive Income Loss Comprehensive Loss
Conclusion Regarding Effectiveness Disclosure Controls Procedures Condemnation
Conditions Offer Conditions Precedent
Conditions Precedent Obligation Parties Consummate Merger Conduct Development Program
Conference Call Information Confidential Information
Confidentiality Confidentiality Information
Consent Independent Registered Public Accounting Firm Consolidated Financial Condition Parent Borrower Subsidiaries Reflected Statements
Consolidated Financial Statements Consolidated Financial Statements Statement Schedule
Consolidation Merger Etc Contacts
Contingent Consideration Expense Continuing Application Plan Terms
Contracts Other Agreements Contractual Obligations
Contributions Controls Procedures
Conversion Securities Conversion Shares Capital Stock Each Issued Outstanding Share
Convertible Convertible Senior Notes
Convertible Subordinated Convertible Subordinated Debentures
Corporate Seal Costs Solicitation
Covenants Covenants Agreements
Covered Transaction Creation Direct Financial Obligation Off-balance Sheet Arrangement
Credit Credit Financial Market Conditions Exacerbate Certain Risk Affecting
Critical Accounting Policies Significant Estimates Critical Accounting Policies Significant Judgments Estimates
Csimma Cumulative Effect Change Accounting Goodwill
Cumulative Effect Change Accounting Principle Current Credit Financial Market Conditions Exacerbate Certain Risk
Current Report Pursuant Securities Exchange Act 1934 Damage Fire
Date Report Earliest Event Reported 2004 Date Report Earliest Event Reported 2005
Date Report Earliest Event Reported 2006 Date Report Earliest Event Reported 2007 Genzyme Corporation
Date Report Earliest Event Reported 2008 Dear Shareholders
Deferral Compensation Defined Benefit Pension Plans
Defined Benefit Plan Accounting Defined Benefits Pension Plans
Defined Contribution Plans Defined Pension Benefit Plan Accounting
Defined Terms Definition Hierarchy
Definitions Delivery
Delivery Title Delivery Title Transportation
Departure Directors Certain Officers Election Appointment Compensatory Departure Directors Certain Officers Election Appointment Compensatory Arrangements
Departure Directors Principal Officers Election Appointment Derivative Financial Instruments
Derivative Instruments Description Amendment Plan
Description Amendments Plan Description Amendments Purchase Plan
Description Business Description Business Summary Significant Accounting Policies
Description Common Stock Designated Shares
Development Approvals Title Exceptions Development Information
Development New Biotechnology Products Involves Lengthy Complex Process Diagnostic Assets Chemicals Limited
Diagnostic Assets Dcl Diagnostics Genetics
Director Compensation Director Selection Criteria
Directors Directors Continuing Office
Directors Deferred Compensation Plan Directors Executive Officers Corporate Governance
Disaster Recovery Plan Disclaimer Warranties
Disclosure Schedule Disclosure Schedule Identifies Each Open Tax Position Such
Discretionary Authority Disposition Assets
Dispositions Dispute Resolution
Dissenting Shares Distributions Changes Capital Stock Basic Adjustment Provisions
Distributor Fees Dividend Equivalents Etc
Dividend Policy Dividends Cash Awards
Dividends Distributions Documentation
Documents Incorporated Reference Douglas Berthiaume
Dow Facility Dyax
Dyax Corp Dyax Corporation
E-1 Each Borrower Shall Repay Outstanding Loans Revolving Termination
Each Plan Subject 409a Code Been Operated Good Each Subsidiary Corporation Other Legal Entity Duly Organized
Early Termination Earnings Allocations
Earnings Per Share Easements Changes Lot Lines
Ecitals Effect Certain Transactions
Effect Termination Effect Waivers Default
Effective 2009 Effective Date Amendment Termination
Election Election Directors
Eligibility Participation Elimination Tracking Stock Structure
Employee Benefit Plans Employee Relations
Employee Stock Purchase Plan Employees
Employer Contributions Employment
Employment Contracts Encounter Substantial Difficulties Managing Growth
End Enforcement Patent Rights
Entire Agreement Survival Entry Material Definitive Agreement
Environmental Matters Except Set Forth Schedule 318 Disclosure Environmental Remediation
Equity Equity Compensation Plan Information
Equity Grant Guidelines Timing Equity Income Loss Method Investments
Equity Income Method Investments Equity Loss Method Investments
Equity Method Investments Equity Plans
Equity Price Risk Espp
Espp Activity Estimated Future Benefit Payments
Estimates Estoppel Certificate
Evaluation Disclosure Controls Procedures Events Default
Exchange Act Exchange Certificates
Exclusivity Execution Documents
Execution Papers Executive Compensation
Executive Compensation Plans Arrangements Executive Employment Agreements
Executive Search Firm Executive Severance Agreement
Executive Severance Agreements Exercise Price Stock Option
Exhibits Exit Activities
Expansion Premises Expectations Respect Majority Voting Election Directors
Expenses Explanatory
Export Control Technical Data Fabrazyme
Fabrazyme Agalsidase Beta Fabrazyme Patent Litigation
Factors Affecting Future Operating Results Factors Discussed Caption Risk Genzymes Quarterly Report Form
Fail Adequately Protect Proprietary Technology Allow Competitors Others Fail Increase Sales Several Existing Products Services Commercialize
Fail Increase Sales Several Existing Products Services Not Fail Increase Sales Several Products Services Not Meet
Fail Obtain Adequate Levels Reimbursement Products Party Payors Fail Obtain Maintain Adequate Levels Reimbursement Products Party
Fail Obtain Maintain Adequate Levels Reimbursement Products Services Fair Market Value
Fair Value Measurement-definition Hierarchy Fair Value Measurements
Fas 151 Inventory Costs Amendment Arb Chapter Fas 157 Fair Value Measurements
Fas 158 Employers Accounting Defined Benefit Pension Other Fas 159 Fair Value Option Financial Assets Liabilities-including
Fda Approval Fda Believes Repeatedly Violated Gmp Requirements Pursue Enforcement
Fda Regulation Federal Income Tax Consequences Relating Plan
Federal Income Tax Consequences Relating Purchase Plan Federal Securities Litigation
Filled Corporation Fin Accounting Uncertainty Income Taxes-an Interpretation Fasb Statement
Financial Advisor Financial Information Regarding Segment
Financial Information Regarding Segment Reporting Financial Information Segments Geographic Areas
Financial Position Financial Reporting Process
Financial Results Financial Results Dependent Sales Cerezyme
Financial Results Highly Dependent Sales Cerezyme Financial Statement Schedules
Financial Statements Financial Statements Exhibits
Financial Statements Supplementary Data Fixed Rent
Fludara Fludarabine Phosphate Injection Following Table Shows 2006 Number Shares Outstanding Available
Following Terms Shall Meanings Food Drugs Regulations
Force Majeure Force Majeure Event
Force Majeure Hardship Foreign Exchange Forward Contracts
Foreign Exchange Risk Foreign Nationals
Form 10-k Form 10-q
Form 10-q 2008 Form 10-q 2009
Form 10-q Amendment Form Awards
Form Options Form Supply Agreement
Forward-looking Statement Forward-looking Statements
Fractional Shares Funding Receivable
Future Success Depend Ability Effectively Develop Market Products Gail Boudreaux
Gail Koziara Boudreaux Gain Acquisition Business
Gains Investments Equity Securities Gains Investments Equity Securities Net
Gains Losses Investments Equity Securities Gains Losses Investments Equity Securities Net
Gbl West Malling Geltex
Gemayel General
General Disagreements Within Program Management Team Steering Committee General Equity Grant
General Information Voting General Laws Chapter 156d 1007 950 Cmr 11335
General Provisions Applicable Construction General Purpose
Genetic Diseases Genetics
Genetics Pricing Genzyme
Genzyme 2005 Guidance Genzyme Announces Share Repurchase Authorization
Genzyme Corporation Genzyme Corporation 2001 Equity Incentive Plan Officer Tier
Genzyme Corporation 2004 Equity Incentive Plan Officer Restricted Genzyme Corporation Subsidiaries
Genzyme Corporation Subsidiaries Consolidated Selected Financial Data Genzyme Corporation Subsidiaries Financial Statements
Genzyme Corporation Subsidiaries Form 10-q 2007 Signatures Genzyme Drug Discovery Development
Genzyme Flanders Genzyme Formerly Sangstat
Genzyme General Genz Condensed Consolidated Balance Sheets Amounts Genzyme Glycobiology Research Institute
Genzyme Ltd Genzyme On-site Stockroom Programs
Genzyme Pharmaceuticals Genzyme Policy Addresses Important Topic Senior Executive Severance
Genzyme Policy Not Place Competitive Disadvantage Attracting Retaining Genzyme Receives Notice Icahn Partners8217 Nomination Directors
Genzyme Relational Investors Enter Mutual Cooperation Agreement Genzyme Shareholders
Genzyme Stock Genzyme Stock Purchase Rights
Genzyme Temporarily Interrupts Production Allston Plant Genzyme Virotech Gmbh
Genzyme Waterford Genzymes Current Severance Agreements Senior Executives Reasonable Genzyme
Genzymes Severance Agreements Reasonable Necessary Geographic Information
Geographic Segments Gmps
Good Manufacturing Practices Goodwill
Goodwill Other Intangible Assets Governing Law
Governing Law Agreement Shall Governed Construed Interpreted Accordance Governing Law Assumption Agreement Shall Governed Construed Interpreted
Governing Law Guarantee Shall Governed Construed Interpreted Accordance Government Regulation
Government Regulation Imposes Significant Costs Restrictions Development Commercialization Grant Awards
Grant Options Grant Options Option Terms
Grants Restricted Stock Units Greement
Gross Gains Investments Gross Gains Investments Equity Securities
Gross Margin Gross Product Profit Margin
Gross Profit Margins Gross Profit Product Margin
Gross Service Profit Margin Gtc
Gtc Biotherapeutics Gtc Biotherapeutics Inc
Guarantee Guidance
Guidelines Recommendations Published Various Organizations Reduce Products Guidelines Recommendations Studies Published Various Organizations Reduce Products
Hazards Risk Sharing Headings
Hectorol Hectorol Doxercalciferol
Hectorol Patent Litigation Hematologic Oncology
Henri Termeer Henry Blair
Holdover However
Ilex Ilex Oncology
Immediate Release Immune Infectious Diseases
Impact Employee Status Impairment Goodwill
Impairment Goodwill Indefinite-lived Iprd Impairment Tangible Intangible Assets Other Goodwill
Impairment Tangible Intangible Assets Other Goodwill Finite-lived Iprd Important Additional Information Filed Securities Exchange Sec
Important Information Important Information Regarding Proxy Solicitation
Important Information Regarding Tender Offer Importation Products Canada Other Countries United States Lower
Importation Products Lower Prices Receive In-process Research Development
Incentive Bonuses Incentive Stock Option Terms Conditions
Income Tax Allocation Policy Income Taxes
Incur Substantial Costs Result Litigation Other Proceedings Ind
Indemnification Indemnification Directors Officers
Indemnity Independence Discussions Audit Committees
Independent Auditors Index
Index Consolidated Financial Statements Index Exhibits
Individually Requires Contemplates Aggregate Expenditures Subsidiary Period 100000 Initial Term
Inspection Notice Claims Installation Alterations Additions
Insurance Insurance Taken Out Landlord
Insurance Taken Out Tenant Intellectual Property
Intellectual Property Rights Interest Expense
Interest Rate Risk Interest Shall Payable Arrears Each Payment Date Provided
Interested Directors Officers Internal Control Over Financial Reporting
International Invoices International Product Service Revenue
International Sales Operating Expenses Subject Fluctuations Currency Exchange International Sales Operations Subject Economic Political Legal Business
International Sales Subject Fluctuations Currency Exchange Rates Introduction
Inventories Inventories Amounts
Investment Income Investments
Investments Debt Equity Securities Investments Equity Securities
Investments Marketable Securities Subject Market Interest Credit Risk Invoices
Invoices Payment Iprd
Isis Isis Pharmaceuticals Inc
Iso Issuance Stock Subsidiary Affiliate
Issuer Purchases Equity Securities Joint Committees
Joint Venture Biomarin Joint Venture Biomarin Pharmaceutical Inc
Kendall Street Kendall Street Cambridge Massachusetts 02142
Kendall Street Cambridge Massachusetts 02142 Address Principal Executive Kidney Disease
Landlord Landlord Indemnity Correction Landlords Work
Landlords Default Landlords Expenses Consents
Landlords Right Cure Defaults Landlords Right Enter
Late Payment Rent Law Certificate Incorporation By-laws
Lease Amendments Lease Not Recorded
Legal Compliance General Legal Conditions Delivery Stock
Legal Proceedings Legislative Regulatory Changes Adversely Impact Business
Letters Authorization Level Indebtedness Harm Financial Condition Results Operations
License Co-development Agreement Licenses Rights Biomarin Genzyme Llc
Limitation Remedies Liability Limitation Rights
Limited Warranty Limits
Liquidation Dissolution Winding Liquidity Capital Resources
List Remediation Documents Loading
Loans Long-lived Intangible Assets
Long-term Debt Capital Lease Obligations Long-term Debt Capital Lease Obligations Convertible
Loss Investment Equity Securities Loss Investments Equity Securities
Losses Investments Equity Securities Net Lymphoglobuline Anti-thymocyte-globuline Equine
Managements Annual Report Internal Control Over Financial Reporting Managements Discussion Analysis Financial Condition Results Operations
Managements Discussion Analysis Genzyme Corporation Subsidiaries Financial Condition Managements Report Internal Control Over Financial Reporting
Manufacture Sale Manufacture Supply Collaboration Products Biomarin Genzyme Llc Shall
Manufacture Supply Sales Marketing Manufacturing
Manufacturing Investments Manufacturing Marketing Sales Agreement
Manufacturing Problems Cause Product Launch Delays Inventory Shortages Manufacturing Problems Caused Inventory Shortages Unanticipated Costs Future
Manufacturing Raw Materials Manufacturing Regulatory Issues 2009
Margins Market Benchmarking
Market Risk Marketing Distribution Agreements
Massachusetts Control Share Acquisition Act Maximum Liability Such Guarantor Hereunder Until Borrower Obligations
Meanings Given Terms Defined Herein Shall Equally Applicable Meetings
Merger Merger Agreement Shall Been Terminated Accordance Terms
Merger-step Mergers Acquisitions
Mergers Acquisitions Strategic Transactions Minimis
Minority Interest Miscellaneous
Modification Certain Definitions Certificate Regarding Commencement Date Modrenal
Molecular Oncology Stock Monopolistic States North Dakota Ohio Wyoming West Virginia
Mortgage Mortgage Payable
Moscicki Mozobil Plerixafor Injection
Mps Mutual Written Consent Parent Duly Authorized Board Directors
Myozyme Myozyme Alglucosidase Alfa
Myozyme Lumizyme Nature Business Organization
Nda Negative Covenants
Negative Covenants Pending Closing Shall Not Net Income Loss Per Share
Net Income Per Share Net Income Per Share Genzyme Stock
New Hire Stock Option Grant Nominating Corporate Governance Committee
Non-gaap Excludes Impact Amortization One-time Events Fas123r Expense Non-us Stock Options Restricted Units
Nonstatutory Stock Option Terms Conditions Nonstatutory Stock Options
Not Party Commitment Become Joint Venture Off-balance Sheet Notes
Notes Payable Notes Pro Forma Combined Financial Statements
Notes Receivable Shareholders Notes Receivable Stockholders
Notice Notice Annual Meeting Shareholders Genzyme Corporation
Notice Sale Shares Required Participant Agrees Notify Writing Notices Party Other
Notification Patent Term Restoration Biomarin Shall Notify Genzyme Notwithstanding Above Administrator Not Take Actions Hereunder Award
Notwithstanding Above Administrator Not Take Actions Hereunder Stock Novazyme
Now Therefore Nuisance
Number 0-14680 Number Shares
Objectives Overview Executive Compensation Occupancy
Occurrence Claims-made Off-balance Sheet Arrangements
Offer Officers Agents
Oligon Oncology
Oncology Drugs Onference Call Information
Operating Guidelines Operating Leases
Operating Results Financial Position Impacted Attempt Grow Through Operating Results Financial Position Negatively Impacted Attempt Grow
Option Acceleration Change Control Option Exercises Stock Vested
Options Extend Orphan Drug Act
Orthopaedics Osiris Therapeutics Inc
Other Other Commitments Contingencies
Other Compensation Arrangements Other Events
Other Genetic Diseases Other Government Regulation
Other Income Expenses Other Intangible Assets
Other Laws Regulations Other Matters
Other Product Revenue Other Reserve Estimates
Ownership Disposition Such Regulatory Approvals Event Agreement Terminated Parking
Part Part Other Information
Participant Parties
Party Party Agreements
Party Licenses Patents License Agreements Trademarks
Payment Payment Deferred Compensation
Payment Landlords Cost Enforcement Payment Receivable Dyax
Payment Receivable Dyax Corp Payment Stock Option
Payments Account Taxes Insurance Utilities Pending Acquisition Anormed
Pending Acquisition Bayer Pending Acquisition Bioenvision
Pending Acquisition Diagnostics Division Diagnostic Chemicals Limited Pending Merger Bone Care International
Peptimmune Perform Obligations
Performance Tenants Work Periodically Review Severance Arrangements Ensure They Competitive Make
Personal Property Tenants Risk Persons Eligible Participate Plan
Pipeline Outlook Plan
Plan Defined Calendar Although Terms Apply Through Date Plant Visits
Pledge Capital Stock Grant Security Interest Pledged Stock
Policies Relating Tracking Stocks Effect Through 2003 Policy Corporate Aircraft
Portion Principal Amount Loan Reimbursement Obligation Shall Not Potential Payments Termination Change Control
Preceding Articles Considered Permanent Changed Only Filing Appropriate Preclinical Clinical Activities Following Terms Conditions Such Other
Preferred Stock Premises
Preparation Premises Performance Tenants Work Price
Price Orders Terms Payment Pricing Reimbursement
Principal Accounting Fees Services Principles Consolidation
Pro Forma Combined Balance Sheets Genzyme Pro Forma Combined Financial Information
Pro Forma Combined Statements Operations Genzyme Pro Forma Financial Summary
Pro Forma Information Period Prior Adoption Fas 123r Procedure
Process Philosophy Setting Executive Compensation Product Margin
Product Pipeline Product Pricing
Product Sales Product Sales Allowances
Product Specifications Product Stewardship
Products Program Funding
Program Funding Capital Contributions Program Management Team
Project Project Budget Form
Properties Property
Property Plant Equipment Proposal Amend 1999 Employee Stock Purchase Plan
Proposal Amend 2004 Equity Incentive Plan Proposal Amend Bylaws Provide Majority Vot Ing Election
Proposal Amend Restate Charter Proposal Approve 2007 Director Equity Plan
Proposal Approve 2009 Employee Stock Purchase Plan Espp Proposal Ratify Selection Auditors
Proposals Vote Recommendation Proposed Acquisition Add Complementary Late-stage Transplant Product
Proprietary Information Provided
Provided However Provided Yearly Business Review
Provides Outlook Growth 2006 Provision Benefit Income Taxes
Provision Income Taxes Proxies
Proxy Material Mailing Date Proxy Solicited Behalf Board Directors
Proxy Solicited Behalf Board Directors Genzyme Common Stock Proxy Statement Prepared Shareholder Meeting Merger
Proxy Statement Pursuant Securities Exchange Act 1934 Amendment Proxy Voting Instructions
Ptc Therapeutics Inc Purchase In-process Research Development
Purchase Intellectual Property Exact Sciences Purchase Intellectual Property Exact Sciences Corporation
Purchase Price Allocation Purchase Rights
Purpose Purposes Agreement
Pursuant Quantitative Qualitative Analysis Market Risk
Quantitative Qualitative Disclosures Market Risk Quarterly Results
Quiet Enjoyment Quorum
Rank Ratification Audit Committees Selection Independent Auditors 2009
Raw Materials Rcra
Re-election Directors One-year Terms Reacquired Shares
Real Estate Taxes Realized Unrealized Gains Losses Marketable Securities Investments Equity
Receivable Dyax Receivable Dyax Corp
Receivable Dyax Corporation Recent Accounting Pronouncement
Recent Accounting Pronouncements Recitals
Recognition Stock Option Grant Regarding Forward-looking Statements
Regarding Incorporation Reference Regarding References Common Stock
Regarding References Genzyme Regarding References Genzyme Corporation
Regarding Trademarks Regulation Diagnostic Products
Regulation Diagnostic Testing Services Regulation Disclosure
Regulation Gene Therapy Products Regulation Outside
Regulation Outside United States Regulatory Authorities Fail Approve Pending Applications Timely Matter
Regulatory Authority Regulatory Filings Reasonable Efforts
Reimbursement Outside United States Reiterates Outlook
Rely Parties Provide Materials Services Connection Manufacture Products Remainder Page Intentionally Left Blank
Remedial Provisions Remedies
Remedies Cumulative Removal
Renagel Renagel Renvela Patent Litigation
Renagel Sevelamer Hydrochloride Renal
Renamed Renamed Collaboration
Repair Maintenance Repairs
Report Independent Registered Public Accounting Firm Report Independent Registered Public Accounting Firm Financial Statement
Reporting Person Reports Review
Representations Warranties Representations Warranties Parent
Representations Warranties Parent Sub Representatives
Require Significant Additional Financing Not Available Favorable Terms Required License Patents Competitors Others Order Develop Commercialize
Required License Technology Competitors Others Order Develop Commercialize Research Development
Research Development Costs Research Development Expenses
Research Development Programs Research Development Revenue
Research Related Product Reservation Rights
Resignations Removals Resolved
Respect Property Other Proprietary Rights Each Subsidiary Assets Restated Articles Organization General Laws Chapter 156d 1007
Restricted Cash Restricted Stock
Restricted Stock Unit Restructuring Plans
Results Operations Results Operations Financial Condition
Results Voting Retail Tenants
Revenue Guidance Revenue Recognition
Revenues Revoke Proxy Instructions
Revolving Credit Facility Richard Syron
Richard Syron Elected Genzymes Board Directors Right Refusal
Rights Limited Rights Mortgage Holders
Rights Product Rights Stockholder
Risk Factors Risks Uncertainties
Robert Carpenter Rules Applicable Awards
Rules Applicable Stock Options Restricted Units Rules Construction Certain Definitions
Rules Regulations Sab 108
Sab 108 Considering Effects Prior Misstatements Quantifying Current Safe Harbor Statement
Safety Data Alemtuzumab Phase Trial Sales Geographic Area Significant Customers Products
Sales Marketing Sales Marketing Product Pricing
Sandford Smith Sangstat
Sargramostim Schedule
Schedule 14a Schedule 14a Rule 14a-101 Information Required Proxy Statement
Schedule 301a Schedule 312
Schedule Ii-valuation Qualifying Accounts 2005 2004 2003 Schedule Ii-valuation Qualifying Accounts 2007 2006 2005
Scope Structure Collaboration Seal
Sec Filings Secretary Commonwealth
Security Ownership Certain Beneficial Owners Management Related Stockholder See Attachment Other Lawful Provisions
See Notes Pro Forma Combined Statement Operations Segment Assets
Segment Information Selected Financial Data
Selling General Administrative Expenses Senator Connie Mack
Sepra Products Series Preferred Stock
Service Margin Service Revenue
Setting 2006 Base Salary Target Annual Incentives Other Sevelamer Carbonate
Sga Expenses Shall Pay Such Lender Additional Amount Amounts Compensate
Share Certificates Shareholder Approval
Shareholder Communications Board Directors Shareholder Demand Letters
Shareholder Derivative Actions Shareholder Nominations Directorships
Shareholder Proposal Create Uncertainty Regarding Existing Arrangements Shareholder Proposal Executive Severance Agreements Approved Shareholders
Shareholder Proposal Executive Severance Arrangements Approved Shareholders Shareholder Proposals
Shareholder Support Agreements Shareholder Vote Required Certain Actions
Shares Pledged Stock Been Duly Validly Issued Fully Shares Subject Plan
Shortfall Signage
Signature Signature Authorized Individual
Signatures Solicitation
Some Products Face Competition Lower Cost Generic Follow-on Special Requirements Genzymes Belgium Facility
Specially Regulated Waste Specification
Specifications Specifications Cofa
Spending Statement Board Directors
Steering Committee Stock Available Grant Limits
Stock Compensation Plans Stock Option
Stock Option Plan Activity Stock Option Plans
Stock Options Stock Performance Graph
Stock Repurchase Stock Repurchase Program
Stock Rights Stock Transfer Books
Stock-based Compensation Stock-based Compensation Expense Net Estimated Forfeitures
Stockholder Approval Stockholder Approval Merger
Stockholders Stockholders Meeting
Strategic Alliance Isis Strategic Alliance Isis Pharmaceuticals Inc
Strategic Alliance Osiris Strategic Alliance Osiris Therapeutics Inc
Strategic Alliance Ptc Strategic Alliances
Strategic Alliances Unsuccessful Operating Results Adversely Impacted Strategic Alliances Unsuccessful Operating Results Negatively Impacted
Strategic Equity Investments Strategic Management
Strategic Transactions Studies Required Regulatory Authorities
Subdivision Sublicenses Rights Biomarin Genzyme Llc
Submission Matters Vote Security Holders Submission Not Offer
Subsequent Events Subsidiaries
Subsidiaries Registrant Such Payment Received Swingline Lender Required Returned Return
Summary Equity Compensation Program Superiority Lease Option Subordinate
Supplemental Product Amendment Biosurgery Products Supply After 2008 Forecasting Before Nda Filing
Supply Forecasting After Nda Filing Support Agreement
Supporting Statement Synvisc
Synvisc Hylan G-f Table Contents
Take Action Before After Award Grant Deems Advisable Tax Law Limits Executive Compensation
Tax Matters Tax Rate
Taxes Technical Agreement
Technology License Fees Technology Transfer Fee
Technology Transfer Supply Agreement Tem
Tenant Reimbursement Insurance Taken Out Landlord Tenants Work
Tender Offer Tender Offer-step
Tender Voting Agreement Term
Term Termination Term Termination Prior Manufacturing Agreement
Termeer Termeers Compensation
Termination Amendment Waiver Termination Cause
Termination Development Program Only Termination Employment
Termination Material Definitive Agreement Termination Outside Change Control
Terms Conditions Territory Shall Mean World
Therapeutics Thursday 2007
Thymoglobulin Anti-thymocyte Globulin Rabbit Thymoglobulin Lymphoglobuline
Thyrogen Thyrogen Thyrotropin Alfa
Tier Not Retirement Eligible Time Manner Exercise Stock Option
Time Vesting Rsu Activity Time-vested Rsu Activity
Title Corporate Operations Pharmaceuticals Top-up Option
Transaction Terms Transactions Affiliates
Transfer Shares Stock Transferability
Translation Foreign Currencies Transplant
Uncertainties Undesignated Preferred Stock
Unless Administrative Agent Shall Been Notified Writing Relevant Unrealized Gains
Unrealized Gains Losses Unrealized Gains Losses Marketable Securities Equity Investments
Unrealized Gains Losses Marketable Securities Investments Equity Unregistered Sales Equity Securities Proceeds
Upcoming Events Update Earnings Release
Utilities Premises Vacancies
Valuation Assumptions Stock Option Plans Espp Valuation Techniques
Venturers Capital Verigen
Vesting Exercisability Victor Dzau
Vote Vote Shares
Votes Counted Voting Procedures-shareholders Record Beneficial Owners
Voting Rights Waiver Jury Trial Pledgor Hereby Irrevocably Unconditionally Waives
Waiver Subrogation Warranties
Warranties Genzyme Waste
What Receive Proxy Card Wherea
Whereas William Francis Galvin
Wirth Withholding Taxes
Within Date Submitted Witness Whereof
Work Written Statement Chief Executive Officer
Written Statement Chief Financial Officer Wwweproxyviewcom Genz
Wyntek Wyzga
Year-end Yield
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki